Back to news

ImmunityBio Named No. 2 Fastest-Growing Technology Company in North America on the 2026 Deloitte Technology Fast 500™

Business Wire•19/11/2026•08:30 ET
0

Key Highlights

  • ➤ImmunityBio (IBRX) ranked No. 2 on Deloitte’s 2026 Technology Fast 500.
  • ➤Revenue grew over 47,000% from 2022 to 2025.
  • ➤2025 net product revenue increased 700% year over year.
  • ➤2026 first-nine-month net product revenue growth reached 92%.
  • ➤ANKTIVA is now authorized in 35 countries.

Expert Statements

Richard Adcock, President and CEO of ImmunityBio

“Ranking No. 2 on the Deloitte Technology Fast 500 list reflects the Company’s significant growth and the expanding adoption of ANKTIVA(®) in the U.S. and globally”

Richard Adcock, President and CEO of ImmunityBio

“Following 700% year-over-year net product revenue growth in 2025, we’ve sustained that momentum with 92% growth through the first nine months of 2026.”

Richard Adcock, President and CEO of ImmunityBio

“As ANKTIVA gains broader clinical adoption, we remain focused on expanding patient access, strengthening our global commercial presence, and delivering long-term value to our stockholders.”

ImmunityBio Named No. 2 Fastest-Growing Technology Company in North America on the 2026 Deloitte Technology Fast 500™

Ranking reflects significant revenue growth over last three years and continued global expansion of ANKTIVA(®), now authorized in 35 countries

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in